ReviewFrontiers in psychiatry2017
Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.
Review in Frontiers in psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 188 citations in OpenAlex.
- Substance Use Disorders and the Psychosis Spectrum: Assessment, Clinical Challenges and Management.Journal of clinical medicine · 2026Review
- Synthetic Cannabinoid Use and Sports-Related Concussion Risk Among US Adolescents: Implications for School Health Screening and Prevention.The Journal of school health · 2026Article
- Knowledge, attitudes, and perception toward new psychoactive substances among Saudi university students: a cross-sectional study.Frontiers in psychiatry · 2026Article
- The mesocorticolimbic system in stimulant use disorder.Molecular psychiatry · 2025Review
- Evidence for enduring cardiac and multiorgan toxicity after repeated exposure to the synthetic cannabinoid JWH-018 in male rats.Toxicology · 2024Article
- Timeframe Analysis of Novel Synthetic Cannabinoids Effects: A Study on Behavioral Response and Endogenous Cannabinoids Disruption.International journal of molecular sciences · 2024Article
- Metabolic Stability and Metabolite Identification of N-Ethyl Pentedrone Using Rat, Mouse and Human Liver Microsomes.Pharmaceutics · 2024Article
- Cannabinoids and the Gastrointestinal Tract.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Review
- Molecular Docking Assessment of Cathinones as 5-HTMolecules (Basel, Switzerland) · 2023Article
- Understanding the Mechanisms of Action and Effects of Drugs of Abuse.Molecules (Basel, Switzerland) · 2023Review
- Acute Cardiovascular and Cardiorespiratory Effects of JWH-018 in Awake and Freely Moving Mice: Mechanism of Action and Possible Antidotal Interventions?International journal of molecular sciences · 2023Article
- Deletion ofFrontiers in pharmacology · 2023Article
- Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management.Frontiers in pharmacology · 2023Review
- Substance use and substance use disorders in Africa: An epidemiological approach to the review of existing literature.World journal of psychiatry · 2022Review
- Poisoning with central stimulant drugs: an observational study from Oslo, Norway.International journal of emergency medicine · 2022Article
- Effects of the Phenethylamine 2-Cl-4,5-MDMA and the Synthetic Cathinone 3,4-MDPHP in Adolescent Rats: Focus on Sex Differences.Biomedicines · 2022Article
- Synthetic Cannabinoid-Related Deaths in England, 2012-2019.Cannabis and cannabinoid research · 2022Article
- Article
- Synaptic changes induced by cannabinoid drugs and cannabis use disorder.Neurobiology of disease · 2022Review
- Synthetic Cathinones: Recent Developments, Enantioselectivity Studies and Enantioseparation Methods.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As part of an increasing worldwide use of designer drugs, recent use of compounds containing cathinones and synthetic cannabinoids is especially prevalent. Here, we reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, and detection of these compounds. Gender differences and clinical effects will also be examined. Chronic use of synthetic cathinone compounds can have major effects on the central nervous system and can induce acute psychosis, hypomania, paranoid ideation, and delusions, similar to the effects of other better-known amphetamine-type stimulants. Synthetic cannabinoid products have effects that are somewhat similar to those of natural cannabis but more potent and long-lasting than THC. Some of these compounds are potent and dangerous, having been linked to psychosis, mania, and suicidal ideation. Novel compounds are developed rapidly and new screening techniques are needed to detect them as well as a rigorous regulation and legislation reinforcement to prevent their distribution and use. Given the rapid increase in the use of synthetic cathinones and cannabinoid designer drugs, their potential for dependence and abuse, and harmful medical and psychiatric effects, there is a need for research and education in the areas of prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.